GeoVax Receives Notice of Allowance For Cancer Vaccine Patent
GeoVax Labs, Inc. (GOVX)
NASDAQ:AMEX Investor Relations:
geovax.com/contact-geovax.html
Company Research
Source: GlobeNewswire
Adds to Growing Portfolio of Intellectual Property Assets ATLANTA, Ga., Dec. 09, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for Patent Application No. 17/876,682 to GeoVax, titled “Vaccinia Viral Vectors Encoding Chimeric Virus Like Particles.” The allowed claims add to GeoVax’s intellectual property protection related to its vector platform for expressing a tumor associated antigen (TAA) in virus-like particles (VLPs) from a recombinant Modified Vaccinia Ankara (MVA) viral vector, further demonstrating the GeoVax technical expertise. The allowed claims encompass GeoVax’s Mucin 1 (MUC1) tumor-associated antigen immunotherapy candidate, MVA-VLP-MUC1. The Company uses its MVA-VLP vaccine platform to express abnormal, aberrantly glycosylated forms of the cell surface-associat
Show less
Read more
Impact Snapshot
Event Time:
GOVX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GOVX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GOVX alerts
High impacting GeoVax Labs, Inc. news events
Weekly update
A roundup of the hottest topics
GOVX
News
- GeoVax Labs, Inc. (NASDAQ: GOVX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $18.00 price target on the stock.MarketBeat
- GeoVax Receives Notice of Allowance For Cancer Vaccine Patent [Yahoo! Finance]Yahoo! Finance
- GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference [Yahoo! Finance]Yahoo! Finance
- GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity ConferenceGlobeNewswire
- GeoVax Labs, Inc. (NASDAQ: GOVX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $18.00 price target on the stock.MarketBeat
GOVX
Earnings
- 11/12/24 - Beat
GOVX
Analyst Actions
- 11/15/24 - HC Wainwright
GOVX
Sec Filings
- 12/18/24 - Form 8-K
- 11/18/24 - Form 8-K
- 11/14/24 - Form SC
- GOVX's page on the SEC website